Factors affecting the prognosis of patients with delayed encephalopathy after acute carbon monoxide poisoning.
OBJECTIVE
Delayed encephalopathy after acute carbon monoxide poisoning (DEACMP) is a disease with poor prognosis. The present study was conducted to determine the factors that affect the prognosis of DEACMP patients.


METHODS
In a retrospective study, 46 DEACMP patients were chosen by the following criteria: (1) a clear history of acute carbon monoxide poisoning, a distinct "lucid interval," and neuropsychologic symptoms; (2) first-time admittance to a hospital (within 1 week of onset of disease); and (3) completion of standard treatment period in our hospital. All patients received hyperbaric oxygen (HBO(2)) treatments.


RESULTS
Fifty percent (23 of 46) of the DEACMP patients showed improvements after HBO(2) treatments. Age, lucid interval, danger-activities of daily living scores (assessed at worst conditions), and complications were related (P < .05) to the prognosis of DEACMP patients, whereas sex, fundamental diseases, HBO(2) treatment in acute stage, intoxication time, unconsciousness duration, and GM1 ganglioside administration were not (P > .05) related to prognosis.


CONCLUSIONS
Hyperbaric oxygen treatment appears useful in treating DEACMP patients; and patients with greater age and more complications, but shorter lucid interval and less danger-activities of daily living scores, are more likely to have poor prognosis.
Hu
Huijun
H
Hyperbaric Oxygen Center of CPLA, Navy General Hospital, Beijing 100048, China.
Pan
Xiaowen
X
Wan
Yi
Y
Zhang
Qi
Q
Liang
Wenbin
W
D000203:Activities of Daily Living; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002249:Carbon Monoxide Poisoning / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy; D016009:Chi-Square Distribution; D005260:Female; D005677:G(M1) Ganglioside / Q000627:therapeutic use; D006801:Humans; D006931:Hyperbaric Oxygenation; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D020258:Neurotoxicity Syndromes / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D055815:Young Adult
D005677:G(M1) Ganglioside